The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone and Consolidated
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Trident Lifeline Ltd reported strong Q3 FY26 results. Standalone revenue from operations rose to ₹2,367.09 lacs vs ₹1,650.88 lacs in Q3 FY25, a growth of about 43%. Standalone net profit grew to ₹401.46 lacs from ₹302.76 lacs, up roughly 33% YoY. For nine months FY26, standalone net profit stood at ₹1,207.93 lacs vs ₹916.14 lacs in the prior year period, with EPS of ₹10.43 vs ₹7.97. On a consolidated basis, including subsidiaries TNS Pharma, TLL Herbal, TLL Parenterals, Trident Mediquip, and TLL Elements, Q3 revenue jumped to ₹2,571.11 lacs from ₹1,182.66 lacs and nine-month PAT climbed to ₹1,210.63 lacs from ₹792.58 lacs. The auditor (A Bafna & Associates) issued an unqualified limited review report. No investor complaints were pending.
Sharp revenue and profit growth driven by subsidiary consolidation and stronger standalone operations is a positive signal for shareholders, likely to be viewed favorably by the market. The expanded group structure adds both growth potential and execution risk going forward.